In the ClarIDHy phase III multicentre trial, 185 patients with IDH1-mutated cholangiocarcinoma (91.4% ICC) whose disease had progressed on standard chemotherapy were randomized to receive either ivosidenib or a placebo [140]. This evidence concerns the gene IDH1 and intrahepatic cholangiocarcinoma.